ArticleCancers2026
Contrast-Enhanced Ultrasound Combined with Methylene Blue for Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients with Initially cN1 Breast Cancer: A Multicenter Prospective Cohort Study.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundReliable axillary restaging after neoadjuvant chemotherapy (NAC) is essential for patients with initially cN1 breast cancer considered for surgical de-escalation. Although radioisotope plus blue dye dual-tracer mapping can reduce the false-negative rate (FNR) of sentinel lymph node biopsy (SLNB), its routine use is limited by radioisotope access, infrastructure requirements, and procedural complexity. We evaluated contrast-enhanced ultrasound (CEUS) combined with methylene blue as a non-radioactive dual-mapping strategy.
methodsIn this two-center prospective cohort study, patients undergoing surgery after NAC were enrolled if they received preoperative CEUS, intraoperative methylene blue mapping, SLNB, and axillary lymph node dissection. The primary analysis focused on patients with initially cN1 disease, whereas cN2-3 patients were included only for exploratory analyses. Detection rate (DR), FNR, predictive values, CEUS-methylene blue concordance, and CEUS performance for predicting SLN metastasis were assessed.
resultsA total of 269 patients were enrolled, including 208 with initial cN1 disease, 45 with cN2 disease, and 16 with cN3 disease. In the cN1 cohort, CEUS plus methylene blue achieved the highest SLN DR (99.04%; 95% CI, 96.56-99.74), followed by CEUS alone (98.08%) and methylene blue alone (71.63%). The FNR was 9.38% (95% CI, 4.37-18.98) for both CEUS plus methylene blue and CEUS alone, versus 12.50% for methylene blue alone. CEUS-methylene blue concordance was 91.16%. For predicting SLN metastasis, CEUS showed 65.52% sensitivity, 86.30% specificity, and 80.39% accuracy. No immediate procedure-related adverse events occurred.
conclusionsCEUS combined with methylene blue showed high SLN detection and a promising false-negative profile in patients with initially cN1 breast cancer after NAC. These findings support further evaluation of this feasible non-radioactive strategy with larger comparative studies, particularly in settings with limited access to radioisotope-guided mapping.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.